National Institutes of Health: Urinary Bladder Neoplasms trials

The registry lists 67 Urinary Bladder Neoplasms studies with National Institutes of Health as lead sponsor. 10 are open to participants now and 20 have results posted.

Early Phase 1 1Phase 1 17Phase 2 34Phase 3 5No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT TrialRecruitingNCT07061964Phase 2
• The Vanguard Study: Testing a New Way to Screen for CancerRecruitingNCT06995898Not applicable
• Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialRecruitingNCT06770582Phase 2
• 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruitingNCT06503146Phase 2
• A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract MalignanciesRecruitingNCT04923178
• En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope DeviceRecruitingNCT04235764
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 2
• Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer TissueRecruitingNCT02379429
• Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant DiseaseRecruitingNCT00026884
• Evaluation for NCI Surgery Branch Clinical Research ProtocolsRecruitingNCT00001823
• Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial CancerTerminatedNCT04936230Phase 2Results posted
• Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial CarcinomaCompletedNCT03513952Phase 2Results posted
• Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)CompletedNCT03258593Phase 1Results posted
• Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 MutationsActive, not recruitingNCT03047213Phase 2Results posted
• Genomic Based Assignment of Therapy in Advanced Urothelial CarcinomaCompletedNCT02788201Phase 2Results posted
• Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and SurvivorsCompletedNCT02233842Results posted
• Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing SurgeryTerminatedNCT02169284Phase 2Results posted
• Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCGCompletedNCT02015104Phase 2Results posted
• Cabozantinib for Advanced Urothelial CancerCompletedNCT01688999Phase 2Results posted
• Imaging Study for FdCyd and THU Cancer TreatmentTerminatedNCT01479348Early Phase 1Results posted
• Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had ChemotherapyTerminatedNCT01339000Phase 2Results posted
• A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)CompletedNCT00978250Phase 2Results posted
• Green Tea Extract in Treating Patients With Nonmetastatic Bladder CancerCompletedNCT00666562Phase 2Results posted
• Pazopanib in Treating Patients With Metastatic Urothelial CancerCompletedNCT00471536Phase 2Results posted
• VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the UrotheliumCompletedNCT00407485Phase 2Results posted
• Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the UrotheliumTerminatedNCT00363883Phase 2Results posted
• Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder CancerCompletedNCT00238420Phase 1/2Results posted
• Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder CancerCompletedNCT00118040Phase 2Results posted
• Sorafenib in Treating Patients With Regional or Metastatic Cancer of the UrotheliumTerminatedNCT00112905Phase 2Results posted
• Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary TractCompletedNCT00112671Phase 2Results posted
• Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA TrialWithdrawnNCT05564416Phase 2
• Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV StudyActive, not recruitingNCT05092958Phase 3
• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyActive, not recruitingNCT04963153Phase 1
• Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial CancerActive, not recruitingNCT04579224Phase 3
• Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary MalignanciesActive, not recruitingNCT04235777Phase 1
• A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE TrialActive, not recruitingNCT04216290Phase 2
• Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerActive, not recruitingNCT04164082Phase 2
• Vaccine Response With NT-I7WithdrawnNCT04054752Phase 1
• Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial CarcinomaActive, not recruitingNCT03854474Phase 1/2
• Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder CancerActive, not recruitingNCT03775265Phase 3
• Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic ChangesActive, not recruitingNCT03375307Phase 2
• Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder CancerCompletedNCT03327883
• Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerActive, not recruitingNCT03237780Phase 2
• Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruitingNCT02496208Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
• Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid TumorsCompletedNCT01352962Phase 1
• Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung CancerTerminatedNCT01282333Phase 1
• Follow-Up of Bladder Cancer Patients From the New England Study of Environment and HealthCompletedNCT00776178
• The New England Bladder Cancer StudyCompletedNCT00342875
• Interdisciplinary Case-Control Study of Bladder Cancer in SpainCompletedNCT00341861
• Calibration of Urine pH Strips for NCI Case-Control Studies on Bladder Cancer and Comparison of DNA Yields From Buccal Cells Collected Through Two Different MethodsCompletedNCT00339443
• Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell CarcinomaCompletedNCT00072150Phase 2
• Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing CystectomyTerminatedNCT00072137Phase 1
• Decitabine in Treating Patients With Advanced Solid TumorsCompletedNCT00030615Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Ixabepilone in Treating Patients With Advanced Urinary Tract CancerCompletedNCT00021099Phase 2
• LMB-9 Immunotoxin in Treating Patients With Advanced Solid TumorsCompletedNCT00019435Phase 1
• Bladder Cancer Case Control Study of Arsenic in WaterCompletedNCT00011518
• Arsenic Trioxide in Treating Patients With Urothelial CancerCompletedNCT00009867Phase 2
• Celecoxib in Treating Patients With Bladder CancerCompletedNCT00006124Phase 2/3
• Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract CancerCompletedNCT00005831Phase 2
• Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the UrotheliumTerminatedNCT00004856Phase 2
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Eflornithine in Treating Patients With Bladder CancerCompletedNCT00003814Phase 3
• Gene Therapy in Treating Patients With Advanced Bladder CancerCompletedNCT00003167Phase 1
• A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the BladderCompletedNCT00001381Phase 1